Beyfortus is not a vaccine. It is a monoclonal antibody, a lab-made protein that provides ready-made protection against respiratory syncytial virus (RSV) in infants and young children. The distinction matters because vaccines and monoclonal antibodies protect the body in fundamentally different ways, and understanding that difference helps explain what Beyfortus does, how long it lasts, and why your child might still need routine vaccinations on the normal schedule.
How Beyfortus Differs From a Vaccine
Vaccines work by exposing the immune system to a weakened or inactivated piece of a pathogen. This triggers the body to build its own antibodies and, critically, to form immune memory cells that stick around for years. That process is called active immunity. It takes time to develop, but the payoff is long-lasting protection.
Beyfortus skips that entire process. Instead of teaching the immune system to make its own defenses, it delivers pre-made antibodies directly into the infant’s body. Those antibodies immediately recognize and neutralize RSV by blocking the virus from entering cells. This is passive immunity: the protective work was already done in a lab, and the infant’s own immune system never had to learn anything. As the Children’s Hospital of Philadelphia explains, “no memory immunity exists” with passive immunization, so once those antibodies naturally break down over weeks to months, the child’s immune system is back to square one against RSV.
That’s the core trade-off. A vaccine builds a defense the body remembers. Beyfortus provides a defense that’s immediately ready but temporary.
Why a Monoclonal Antibody Instead of a Vaccine
Newborns and very young infants have immature immune systems that don’t respond well to traditional vaccines for certain viruses. RSV is one of the leading causes of hospitalization in babies under 12 months, and there’s no approved RSV vaccine for this age group. Beyfortus fills that gap by giving infants borrowed protection during the months when they’re most vulnerable.
The antibody in Beyfortus (called nirsevimab) has been engineered with specific modifications that extend its lifespan in the bloodstream to roughly 71 days at half-strength. That’s long enough for a single injection to cover about five months of protection, which lines up with the length of a typical RSV season.
How Well It Works
Real-world data from the 2024-2025 RSV season across 24 U.S. states, published by the CDC, found Beyfortus was 80% effective at preventing RSV-related ICU admissions in infants. It was 83% effective against acute respiratory failure from RSV.
Protection is strongest in the first two months. During the first 7 to 59 days after the injection, effectiveness against ICU admission was 86%. Between 60 and 183 days, that dropped to 66%. This declining curve is expected with passive immunity: the borrowed antibodies gradually clear from the bloodstream, and there’s no immune memory to take over.
When Infants Receive It
The CDC recommends Beyfortus during October through March in most of the United States, which tracks with RSV season. The ideal timing depends on when the baby is born:
- Babies born during RSV season (October through March): Ideally receive Beyfortus within their first week of life, during the birth hospitalization.
- Babies born outside RSV season (April through September): Receive a single dose shortly before the season begins, typically in October or November.
- High-risk children entering a second RSV season: May also receive a dose before the season starts.
A single injection covers approximately five months of protection based on clinical trial data. Most infants only need one dose per RSV season.
Side Effects
In clinical trials, side effects were uncommon and mild. The most frequently reported were rash (occurring in about 0.9% of infants who received Beyfortus, compared to 0.6% who got a placebo) and injection-site reactions like pain, swelling, or hardness at the shot location (0.3% vs. 0% in the placebo group).
Serious allergic reactions are possible but rare, as with any injectable medication. Signs include facial swelling, difficulty breathing, severe rash or hives, muscle weakness, or a bluish color to the skin or lips.
Why It Appears on the Immunization Schedule
This is where the confusion often starts. The CDC includes Beyfortus on the childhood immunization schedule alongside traditional vaccines, which understandably leads parents to assume it is one. But the CDC’s own materials are clear: “Nirsevimab is a monoclonal antibody given for the prevention of severe RSV disease. Nirsevimab is not a vaccine.” It appears on the schedule because it’s a recommended immunization for infants, and the immunization schedule is the most practical place for pediatricians and parents to track it. The word “immunization” covers both active immunity (vaccines) and passive immunity (antibody products like Beyfortus).
Because Beyfortus doesn’t stimulate the immune system to respond, it won’t interfere with any of your child’s routine vaccines. It can be given at the same visit as other scheduled shots.
How It Compares to Synagis
Before Beyfortus, the only option for RSV prevention in infants was palivizumab (brand name Synagis), another monoclonal antibody. Synagis requires monthly injections throughout RSV season and was only available to high-risk infants, such as those born very premature or with certain heart or lung conditions. Beyfortus is a single shot that lasts roughly five months and is recommended for all infants, not just those at elevated risk. For most families, Beyfortus has replaced Synagis as the standard approach to RSV prevention.